100,000 Bottles Sold and 1,000 Urologists' First Choice Therapy: Promescent Shows PE Promise

LOS ANGELES, Oct. 15, 2013 /PRNewswire/ -- With one hundred thousand bottles of Promescent sold and one thousand urologists recommending the FDA-approved premature ejaculation (PE) treatment as their first-choice therapy, Absorption Pharmaceuticals has reached two major milestones of success in its rapid ascent to become a leader in the field of sexual medicine. Promescent's minimal side effects and maximum results are making it an easy choice for doctors and patients alike.

"Over time Promescent had become the lowest risk and best outcome solution for our patients, so we decided to formalize it as first-line therapy in our protocol," says Alec Koo, CEO of Urology Specialists of Southern California (USSC), California's largest urology group.

A once "taboo" topic, PE is finally becoming a more common conversation between patients and their urologists. These key milestones are proof that the number of men seeking and finding a treatment solution with Promescent is only growing. Prior to Promescent, physicians reluctantly prescribed off-label anti-depressants in the form of SSRIs for patients. Neither the patient nor the physicians were satisfied with the results. 

"In the past, patients were uncomfortable discussing PE but that's starting to change," says Dr. Mark Leo, urologist at Urology Specialists of Nevada, the largest urology group in Southern Nevada. "Like Viagra did for erectile dysfunction 15 years ago, the media attention surrounding effective, easy-to-use solutions like Promescent help open the conversation. Even patients with mild PE or no PE at all are inquiring about normalcy and improving sexual performance."

In addition to superior effectiveness and lack of systemic side effects, two key attributes have greatly contributed to Promescent's rapid rise in popularity: over-the-counter availability and low cost-per-use. "At less than three dollars per typical application, Promescent's price point is accessible to the vast majority of the US population," says Jeff Abraham, CEO of Absorption Pharmaceuticals. "Our growing list of pharmacies are enjoying brisk sales of Promescent along with increased foot traffic from the male demographic."

With a rapidly growing reputation as the first-line therapy for PE, Promescent appears to be making good on its promise to spread awareness and relief of a disorder affecting more than 30 percent of men.

For more information, please visit https://www.promescent.com/.

Contact:
Tyler Barnett
Media Representative
Promescent
Ph. 323.937.1951
Fx. 323.658.1903
[email protected]

SOURCE Absorption Pharmaceuticals

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED